Renal Denervation to Improve Outcomes in Patients With End-stage Renal Disease
Renal Denervation to Improve Outcomes in Patients With End-stage Renal Disease
Sympathetic activation is a hallmark of end-stage renal disease and adversely affects
 cardiovascular prognosis. Hypertension is present in the vast majority of these patients and
 plays a key role in the progressive deterioration of renal function and in the exceedingly
 high rate of cardiovascular events. Selective catheter-based renal denervation has been shown
 to be safe and effective in attaining improved and sustained blood pressure control in
 patients with resistant hypertension and normal renal function. The investigators hypothesize
 that catheter-based renal denervation is a safe and effective intervention to achieve
 sustained reduction in sympathetic nerve activity, BP and target organ damage in hypertensive
 End-Stage Renal Disease (ESRD) patients, which will result in improved cardiovascular
 outcomes.
Inclusion Criteria:

 -  end stage renal disease

 -  hypertension (BP≥140/90mmHg)

 Exclusion Criteria:

 -  Individual has renal artery anatomy that is ineligible for treatment as assessed by
 the interventionalist.

 -  Individual has experienced a myocardial infarction, unstable angina, or a
 cerebrovascular accident within 3 months of the screening visit.